Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. News
Corvus Pharmaceuticals, Inc. Quantitative Score
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Corvus Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Corvus Pharmaceuticals, Inc. Financials
Table Compare
Compare CRVS metrics with: | |||
|---|---|---|---|
Earnings & Growth | CRVS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CRVS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CRVS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CRVS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Corvus Pharmaceuticals, Inc. Income
Corvus Pharmaceuticals, Inc. Balance Sheet
Corvus Pharmaceuticals, Inc. Cash Flow
Corvus Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Corvus Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Mr. Leiv Lea | Chief Financial Officer |
| Dr. William Benton Jones Ph.D. | Senior Vice President of Pharmaceutical Development |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Director |
| Dr. Richard A. Miller M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board |
| Mr. Jeffrey S. Arcara | Senior Vice President & Chief Business Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Leiv Lea | Chief Financial Officer | Male | 1954 | 400.66K |
| Dr. William Benton Jones Ph.D. | Senior Vice President of Pharmaceutical Development | 1966 | 356.1K | |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Director | 1960 | 47K | |
| Dr. Richard A. Miller M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board | 1951 | 38.67K | |
| Mr. Jeffrey S. Arcara | Senior Vice President & Chief Business Officer | Male | 1969 | -- |
Corvus Pharmaceuticals, Inc. Insider Trades
| Date | 27 Jun |
| Name | ORBIMED ADVISORS LLC |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | X-InTheMoney |
| Shares | 1397684 |
| Date | 27 Jun |
| Name | ORBIMED ADVISORS LLC |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1176332 |
| Date | 27 Jun |
| Name | ORBIMED ADVISORS LLC |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | X-InTheMoney |
| Shares | 1397684 |
| Date | 27 Jun |
| Name | Thompson Peter A. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1176332 |
| Date | 27 Jun |
| Name | Thompson Peter A. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | X-InTheMoney |
| Shares | 1397684 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 Jun | ORBIMED ADVISORS LLC | Director, 10 percent owner | Acquired | X-InTheMoney | 1397684 |
| 27 Jun | ORBIMED ADVISORS LLC | Director, 10 percent owner | Disposed | S-Sale | 1176332 |
| 27 Jun | ORBIMED ADVISORS LLC | Director, 10 percent owner | Disposed | X-InTheMoney | 1397684 |
| 27 Jun | Thompson Peter A. | Director, 10 percent owner | Disposed | S-Sale | 1176332 |
| 27 Jun | Thompson Peter A. | Director, 10 percent owner | Disposed | X-InTheMoney | 1397684 |